Clínica e Investigación en Arteriosclerosis is a Spanish-language journal of arteriosclerosis, lipidology and vascular risk, founded in 1989 and published from Barcelona by Elsevier España for the Sociedad Española de Arteriosclerosis.《动脉硬化临床与研究》是一本以西班牙语出版的动脉硬化与脂质学期刊，1989 年创刊，由 Elsevier España 在巴塞罗那代表西班牙动脉硬化学会（Sociedad Española de Arteriosclerosis）出版。
It carries the title of official organ for the Spanish society and for two Latin American bodies, the Sociedad Latinoamericana de Arteriosclerosis and the Sociedad Iberolatinoamericana de Arteriosclerosis.它同时是西班牙与两家拉美学会的正式会刊，另两家为拉丁美洲动脉硬化学会（Sociedad Latinoamericana de Arteriosclerosis）和伊比利亚美洲动脉硬化学会（Sociedad Iberolatinoamericana de Arteriosclerosis）。
The 2025 Journal Impact Factor is 1.9, the CiteScore is 2.9, and the title is indexed in the Emerging Sources Citation Index rather than in the Science Citation Index Expanded.2025 年期刊影响因子为 1.9，CiteScore 为 2.9，收录数据库是 Emerging Sources Citation Index，未进入 Science Citation Index Expanded。
Scope
The stated aim is the promotion of knowledge and continuing medical education on arteriosclerosis and its related disorders, with a deliberate focus on the Spanish-speaking audience in Spain and Latin America.刊物公开的宗旨是推动动脉硬化及相关疾病的知识传播与继续医学教育，重心放在西班牙与拉丁美洲的西语读者身上。
Coverage is multidisciplinary by design, moving from basic vascular science through aetiology and epidemiology to the pathophysiology, diagnosis and treatment of atherosclerotic disease.覆盖范围刻意做成多学科，从基础血管科学出发，经病因学与流行病学，一直走到动脉粥样硬化的病理生理学、诊断与治疗。
Lipids and lipoproteins remain the historical core, with papers on dyslipidaemias, low-density lipoprotein metabolism and lipoprotein(a).脂质与脂蛋白是历史最久的核心，论文涉及血脂异常与低密度脂蛋白代谢，也讨论脂蛋白(a) 在风险评估中的位置。
Vascular biology is handled by a dedicated associate editor, covering endothelial function, plaque instability, vascular ageing and the inflammatory routes that turn risk factors into lesions.血管生物学由专职副编辑负责，涵盖内皮功能与斑块不稳定性，也追踪血管老化以及把危险因素转化为病灶的炎症通路。
Hypertension and global vascular risk are treated together, through risk-factor clustering, risk equations calibrated on Spanish cohorts and the long-term care of patients with established disease.高血压与整体血管风险合并处理，内容包括危险因素聚集、按西班牙队列校准的风险方程，以及确诊患者的长期照护。
Diabetic vascular complications and the metabolic syndrome appear regularly, from insulin resistance and fatty liver through to microvascular and macrovascular outcomes.糖尿病血管并发症与代谢综合征是常设主题，从胰岛素抵抗与脂肪肝一直写到微血管和大血管结局。
Nutrition and lifestyle occupy a large share of the pages, with Mediterranean diet trials, dietary pattern analyses and physical activity studies framed around cardiovascular prevention.营养与生活方式占据大量版面，地中海饮食试验与膳食模式分析都围绕心血管预防设计，体育活动研究同样如此。
Atherothrombosis and haemostasis are covered through antithrombotic therapy, platelet biology and the coagulation factors targeted by newer oral anticoagulants.动脉血栓形成与止血通过抗栓治疗与血小板生物学呈现，也涉及新型口服抗凝药所针对的凝血因子。
Genetic and omics work spans familial hypercholesterolaemia, polygenic risk scores and the metabolomic signatures that separate inherited from acquired dyslipidaemia.遗传与组学内容覆盖家族性高胆固醇血症和多基因风险评分，还延伸到区分遗传性与获得性血脂异常的代谢组特征。
Imaging and vascular function assessment appear as carotid intima-media thickness, arterial stiffness, ankle-brachial index and coronary calcium scoring.影像与血管功能评估方面能看到颈动脉内中膜厚度、动脉僵硬度与踝臂指数，冠状动脉钙化评分也在其中。
Prevention and rehabilitation run from primary prevention in general practice to secondary prevention after vascular events and supervised exercise programmes.预防与康复从全科诊室的一级预防起步，延伸到血管事件后的二级预防，也包括有督导的运动项目。
Epidemiology and clinical trials complete the picture, through cohort descriptions, registry analyses and the consensus documents that the society issues through the journal.流行病学与临床试验补齐了版图，队列描述与注册研究分析都在其中，学会的共识文件也借本刊发布。
Article types are full originals, brief originals, clinical notes and methodological notes, together with commissioned editorials, reviews, special articles and bibliographic commentaries.文体以完整原创论文与短篇原创为主，另有临床病例笔记与方法学笔记，以及约稿社论、综述和文献评论。
Alongside original work the journal runs bibliographic commentaries, a format in which one recent paper is summarised and placed in context for readers outside the field.除原创论文外，刊物还设文献评述一种体裁，把近期一篇论文摘要出来并放在脉络里讲给本领域以外的读者。
History
The society founded the journal in 1989 as a publication of its own, and the first volume carried Barcelona as place of publication with the society itself named as publisher.学会于 1989 年创办本刊，作为自己的出版渠道，首卷出版地记为巴塞罗那，出版者一栏写的就是学会本身。
Volume numbering has run without a break since then, so volume 25 of 2013, where MEDLINE coverage starts, lines up with volume one in 1989.卷号自那时起连续编排，2013 年的第 25 卷正对应 1989 年的第 1 卷，MEDLINE 的收录也恰好从这一卷开始。
Production later moved to Ediciones Doyma, the Barcelona medical publisher whose name still stands in the current NLM imprint for the title.印制随后交给巴塞罗那的医学出版商 Ediciones Doyma，这家机构的名字至今仍留在美国国家医学图书馆的现行出版项里。
Doyma was folded into Elsevier España, and the masthead now names Elsevier España, S.L.U. of Barcelona as publisher, with a second office in Madrid.Doyma 后来并入 Elsevier España，版权页如今把巴塞罗那的 Elsevier España 列为编辑与发行方，马德里另设一处办公地址。
Publication settled into a bimonthly rhythm in 1998, and six numbers now appear each year, running from the January-February issue to November-December, with volume 38 covering 2026.刊期在 1998 年落定为双月刊，如今一年出六期，从年初的双月号排到年末，2026 年出到第 38 卷。
An English edition appears as a separate title, Clínica e Investigación en Arteriosclerosis (English Edition), registered under ISSN 2529-9123, which carries translations of the Spanish contents.英文版以独立刊名出版，即《动脉硬化临床与研究（英文版）》，拥有单独的 ISSN 2529-9123，刊载西语内容的英译。
MEDLINE and PubMed took the journal in at volume 25, number 1, January-March 2013, after more than two decades in which Spanish indexes kept the record.MEDLINE 与 PubMed 从 2013 年第 25 卷第 1 期起收录本刊，此前二十多年，文献记录主要靠西班牙本国索引保存。
The Journal Citation Reports entry came late, with a first Journal Impact Factor awarded in 2023, a fact the editors repeat on the journal home page.进入 Journal Citation Reports 的时间相当晚，第一个期刊影响因子在 2023 年才拿到，编辑部把这件事写在刊页显眼处。
Impact has stayed flat since then rather than climbed, at 1.9 in 2023, 1.9 in 2024 and 1.9 in 2025, with a five-year figure of 1.7.此后影响因子保持平稳而未上升，2023 年、2024 年与 2025 年同为 1.9，五年影响因子为 1.7。
In the 2025 Clarivate release the title sits in the third quartile of PERIPHERAL VASCULAR DISEASE, at rank 65 among 100 journals, inside the Emerging Sources Citation Index.在 Clarivate 2025 年的榜单上，本刊位于外周血管病类目的第三区，100 种期刊里排第 65 位，所属数据库是 Emerging Sources Citation Index。
Output remains modest at about 31 articles a year and 559 citations in the window, with a cited half-life of 4.8 years and 28.85 percent of content as gold open access.产出规模不大，年发文约 31 篇，统计窗口内被引 559 次，被引半衰期 4.8 年，金色开放获取占 28.85%。
Digital release now comes before print, and accepted manuscripts enter an ahead-of-print queue citable by DOI, with online publication averaging 28 days after acceptance.数字发布如今走在纸本之前，录用稿以 DOI 形式进入网络优先队列，平均在录用后 28 天上线。
The section Notas metodológicas, presented in 2023 as a new outlet for methods research on cardiovascular risk, was the subject of a promotional note by the editors.「方法学笔记」栏目 2023 年开设，为心血管风险领域的方法学研究提供出口，编辑部专门撰文推介。
Editors
Xavier Pintó Sala, listed with a Barcelona affiliation, heads the journal as Editor Jefe and stands first on the masthead printed with each volume.主编为署名巴塞罗那的 Xavier Pintó Sala，头衔写作 Editor Jefe，在每卷随刊印出的编委名单中排在首位。
Two research editors share the scientific load, Josep Ribalta of Reus for basic research and Carlos Lahoz of Madrid for clinical research.两位研究编辑分担学术把关，雷乌斯的 Josep Ribalta 负责基础研究，马德里的 Carlos Lahoz 负责临床研究。
Three regional editors serve Latin America, Carlos Ignacio Ponte Negretti for Venezuela, Raul Santos for Brazil and Ivan Dario Sierra for Colombia.三位地区编辑服务拉丁美洲，分别是委内瑞拉的 Carlos Ignacio Ponte Negretti、巴西的 Raul Santos 与哥伦比亚的 Ivan Dario Sierra。
Nine associate editors hold named portfolios, carrying the journal into primary care, secondary prevention, lipid metabolism and vascular biology, among other fields.九位副编辑各有明确分工，把刊物带进基层医疗与二级预防，也带进脂质代谢与血管生物学。
The list includes Vicente Pascual for primary care, Agustín Blanco-Echevarría and Estibaliz Jarauta Simon for secondary prevention, and María José Ariza Corbo for lipid metabolism.名单里可见 Vicente Pascual 主管基层医疗，Agustín Blanco-Echevarría 与 Estibaliz Jarauta Simon 主管二级预防，María José Ariza Corbo 主管脂质代谢。
Pablo Pérez-Martínez covers nutrition, Jose A. Páramo covers thrombosis, Carlos Fernández Hernando covers genetics and Núria Amigó Grau covers lipidomics and metabolomics.Pablo Pérez-Martínez 负责营养，Jose A. Páramo 负责血栓，Carlos Fernández Hernando 负责遗传学，Núria Amigó Grau 负责脂质组学与代谢组学。
A scientific council of ten senior figures advises the title, among them Valentín Fuster and Juan José Badimon in New York, José María Ordovás in Boston and Pilar Galan in Paris.十位资深学者组成学术委员会提供咨询，其中有纽约的 Valentín Fuster 与 Juan José Badimon，波士顿的 José María Ordovás，以及巴黎的 Pilar Galan。
The wider editorial committee runs to several dozen specialists, drawn mainly from Spanish hospitals and universities, with members in Chile, Mexico, Argentina and the Netherlands.更外圈的编委会由数十位专家构成，主要来自西班牙的医院与大学，智利、墨西哥、阿根廷与荷兰也有成员。
Peer review is double blind, as the guidelines state under the heading Revisión doble ciego, with author and reviewer identities hidden in both directions.同行评审采用双盲，投稿须知在「Revisión doble ciego」条目下写明作者与评审人的身份双向隐去。
Editorial speed is published as a selling point, with a median of 9 days to first decision, 42 days to the end of review and 28 days from acceptance to online.编辑效率被当作卖点公布，首次决定中位 9 天，评审走完中位 42 天，录用至上线中位 28 天。
Manuscripts arrive through Elsevier's Editorial Manager installation, which also carries the revision and decision workflow for the title.稿件经 Elsevier 的 Editorial Manager 系统投递，返修与决定流程在同一平台内完成。
Editorials, reviews and special articles are commissioned by the editorial office, and authors who wish to propose a review must write to the editors before submitting.社论与综述一类内容由编辑部约稿，作者若想主动提交综述，须先写信与编辑部沟通。
The English edition follows the same guidelines, and it republishes the contents in translation under the second number, so Spanish and English versions of a paper sit side by side.英文版沿用同一套投稿须知，把内容译出后以另一个刊号重新出版，一篇论文因此有西语与英语两个版本并存。
Language policy is pluricentric, accepting all regional norms of Spanish and leaving non-peninsular usage uncorrected, which the editors present as preserving linguistic variety.语言政策采取多中心立场，接受西班牙语各地区的规范，对不按西班牙本土用法写作的稿件不加改写，编辑部把这看作保存语言多样性。